The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)
Background: Docetaxel is a widely used cytotoxic agent. This study evaluates the impact of docetaxel toxicities on patient's health-related quality of life (QoL). Patients and methods: We conducted a multicenter, prospective, non-interventional trial, in which the QoL was assessed using the EOR...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
9 March 2015
|
| In: |
Annals of oncology
Year: 2015, Jahrgang: 26, Heft: 6, Pages: 1244-1248 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdv129 |
| Online-Zugang: | Verlag, teilw. kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdv129 Verlag, teilw. kostenfrei, Volltext: https://academic-oup-com.ezproxy.medma.uni-heidelberg.de/annonc/article/26/6/1244/161784 
|
| Verfasserangaben: | S.-E. Al-Batran, W. Hozaeel, F.K. Tauchert, R.-D. Hofheinz, A. Hinke, C. Windemuth-Kieselbach, A. Hübner, M. Burmester, M. Koenigsmann, J. Wiegand, G. zur Hausen, B. Linsse, R. Kuhl and C. Pauligk for the Arbeitsgemeinschaft Internistische Onkologie (AIO) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1566378877 | ||
| 003 | DE-627 | ||
| 005 | 20230426064429.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171214s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdv129 |2 doi | |
| 035 | |a (DE-627)1566378877 | ||
| 035 | |a (DE-576)496378872 | ||
| 035 | |a (DE-599)BSZ496378872 | ||
| 035 | |a (OCoLC)1340983501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Batran, Salah-Eddin al- |e VerfasserIn |0 (DE-588)114597359 |0 (DE-627)626875730 |0 (DE-576)323432840 |4 aut | |
| 245 | 1 | 4 | |a The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax) |c S.-E. Al-Batran, W. Hozaeel, F.K. Tauchert, R.-D. Hofheinz, A. Hinke, C. Windemuth-Kieselbach, A. Hübner, M. Burmester, M. Koenigsmann, J. Wiegand, G. zur Hausen, B. Linsse, R. Kuhl and C. Pauligk for the Arbeitsgemeinschaft Internistische Onkologie (AIO) |
| 264 | 1 | |c 9 March 2015 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.12.2017 | ||
| 520 | |a Background: Docetaxel is a widely used cytotoxic agent. This study evaluates the impact of docetaxel toxicities on patient's health-related quality of life (QoL). Patients and methods: We conducted a multicenter, prospective, non-interventional trial, in which the QoL was assessed using the EORTC QLQ-C30 questionnaires at baseline and every 4 weeks up to 40 weeks in patients receiving a docetaxel-based chemotherapy for metastatic disease. Treatment-related adverse events were correlated with the corresponding QoL scores. Uni- and multivariate analyses were applied. Results: From January 2008 to June 2011, a total of 2659 patients were included. The majority of patients (48.1%) had prostate cancer, followed by breast (17.1%) and non-small-cell-lung cancer (15.8%). Patients received a median of 5 docetaxel cycles with the median dose of 75 mg/m2. The presence of grade 3/4 diarrhea showed the strongest effect on global health status/QoL average scores (50.91 versus 33.06), followed by vomiting (50.91 versus 35.17), dyspnea (50.94 versus 35.81), mucositis/stomatitis (50.88 versus 36.41), nausea (50.91 versus 36.68), infection (50.90 versus 37.14), fatigue (50.90 versus 43.82) and anemia (50.91 versus 41.03), P < 0.05 for all comparisons. Grade 3/4 leukopenia/neutropenia, alopecia, constipation, neurotoxicity and nail disorders had no significant impact on the global health status/QoL or other items. Conclusion: In this large non-interventional trial, docetaxel-associated grade 3 or 4 toxicities were shown to have a strong detrimental effect on patient's QoL. Notably, diarrhea and vomiting had the strongest negative impact on QoL measures. This has to be kept in mind while making therapeutic decisions and providing optimized supportive treatment measures. | ||
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 26(2015), 6, Seite 1244-1248 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax) |
| 773 | 1 | 8 | |g volume:26 |g year:2015 |g number:6 |g pages:1244-1248 |g extent:5 |a The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdv129 |x Verlag |x Resolving-System |z teilw. kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic-oup-com.ezproxy.medma.uni-heidelberg.de/annonc/article/26/6/1244/161784 |x Verlag |z teilw. kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171214 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 65500 |e 60000PH121917517 |e 65500PH121917517 |k 0/60000/ |k 1/60000/65500/ |p 4 | ||
| 999 | |a KXP-PPN1566378877 |e 2989932038 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title":"The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)","title_sort":"impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)"}],"person":[{"family":"Batran","display":"Batran, Salah-Eddin al-","given":"Salah-Eddin al-","role":"aut"},{"display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut","family":"Hofheinz"}],"name":{"displayForm":["S.-E. Al-Batran, W. Hozaeel, F.K. Tauchert, R.-D. Hofheinz, A. Hinke, C. Windemuth-Kieselbach, A. Hübner, M. Burmester, M. Koenigsmann, J. Wiegand, G. zur Hausen, B. Linsse, R. Kuhl and C. Pauligk for the Arbeitsgemeinschaft Internistische Onkologie (AIO)"]},"relHost":[{"pubHistory":["1.1990 -"],"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"language":["eng"],"part":{"volume":"26","year":"2015","text":"26(2015), 6, Seite 1244-1248","issue":"6","extent":"5","pages":"1244-1248"},"recId":"320428796","origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","dateIssuedKey":"1990"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["320428796"],"issn":["1569-8041"],"zdb":["2003498-2"]},"disp":"The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)Annals of oncology","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}]}],"note":["Gesehen am 14.12.2017"],"id":{"eki":["1566378877"],"doi":["10.1093/annonc/mdv129"]},"physDesc":[{"extent":"5 S."}],"recId":"1566378877","origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"9 March 2015"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a BATRANSALAIMPACTOFDO9201 | ||